Newsroom press releases

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)

Products Molecular

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)

Acquisition / Partnership

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)

Products Molecular

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)

Products Molecular

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)

Acquisition / Partnership

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)

Products Molecular

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)

Acquisition / Partnership

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)

Acquisition / Partnership

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)

Products Immunodiagnostic

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)

Products Immunodiagnostic

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)

Products Immunodiagnostic

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)

Products Immunodiagnostic

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)

Products Molecular

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)

Products Immunodiagnostic